Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 11:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

1d ago ASTELLAS PHARMA : Qiagen Enters into Agreement with Astellas Pharma
2d ago ASTELLAS PHARMA : Announces Revision of Dividend Forecast (Increase Dividends) f..
3d ago ASTELLAS PHARMA : Europe's XTANDI (Enzalutamide) Capsules Garners Positive CHMP ..
5d ago ASTELLAS PHARMA : -xtandi (enzalutamide) capsules receive positive chmp opinion ..
10/22 ASTELLAS PHARMA : Teams Up with USA Rugby and Men's Health Network to Encourage ..
10/22 ASTELLAS PHARMA : Announces Research Collaboration With Harvard Medical School I..
10/22 ASTELLAS PHARMA : Announces Revision of Package Insert in Japan for XTANDI (enza..
10/21 ASTELLAS PHARMA : Announces Revision of Package Insert in Japan for XTANDI® (enz..
10/17 ASTELLAS PHARMA : Partners with USA Rugby and Men's Health Network
10/16 ASTELLAS PHARMA : and CoMentis to End Agreement to Collaborate on Research, Deve..
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes